Roche entered into a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in Phase 2 trials for the treatment of hypertension. Alnylam and Roche will co-commercialize zilebesiran in the U.S. and share cost and profits equally. Outside the U.S. Roche obtains exclusive commercialization rights. Alnylam will lead a joint clinical development plan for the first indication with Roche’s participation, which includes a cardiovascular outcom...